LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 33 of 497
Next
>>
>
801 to 825 of 12420 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Relative Growth Rate After Treatment
BT-20	CP466722	0.37	uM	LJP5	3	I10	72	hr	1657	5783	5505	1.0504	1.0721
BT-20	Crizotinib	0.37	uM	LJP5	1	A22	72	hr	1657	5074	5505	0.9216	0.8878
BT-20	Crizotinib	0.37	uM	LJP5	2	A22	72	hr	1657	4643	5505	0.8433	0.7758
BT-20	Crizotinib	0.37	uM	LJP5	3	A22	72	hr	1657	4707	5505	0.8549	0.7924
BT-20	Momelotinib	0.37	uM	LJP5	1	P10	72	hr	1657	4180	5505	0.7592	0.6555
BT-20	Momelotinib	0.37	uM	LJP5	2	P10	72	hr	1657	4433	5505	0.8052	0.7212
BT-20	Momelotinib	0.37	uM	LJP5	3	P10	72	hr	1657	4543	5505	0.8252	0.7498
BT-20	Dasatinib	0.37	uM	LJP5	1	D04	72	hr	1657	1931	5505	0.3507	0.0710
BT-20	Dasatinib	0.37	uM	LJP5	2	D04	72	hr	1657	1762	5505	0.3200	0.0271
BT-20	Dasatinib	0.37	uM	LJP5	3	D04	72	hr	1657	1989	5505	0.3613	0.0861
BT-20	Dasatinib	0.37	uM	LJP6	1	I04	72	hr	1657	1800	5505	0.3269	0.0370
BT-20	Dasatinib	0.37	uM	LJP6	2	I04	72	hr	1657	1539	5505	0.2795	-0.0309
BT-20	Dasatinib	0.37	uM	LJP6	3	I04	72	hr	1657	1697	5505	0.3082	0.0102
BT-20	Dovitinib	0.37	uM	LJP5	1	E22	72	hr	1657	3998	5505	0.7262	0.6082
BT-20	Dovitinib	0.37	uM	LJP5	2	E22	72	hr	1657	2630	5505	0.4777	0.2527
BT-20	Dovitinib	0.37	uM	LJP5	3	E22	72	hr	1657	2868	5505	0.5209	0.3145
BT-20	Enzastaurin	0.37	uM	LJP5	1	D16	72	hr	1657	6113	5505	1.1103	1.1578
BT-20	Enzastaurin	0.37	uM	LJP5	2	D16	72	hr	1657	6115	5505	1.1107	1.1584
BT-20	Enzastaurin	0.37	uM	LJP5	3	D16	72	hr	1657	6156	5505	1.1181	1.1690
BT-20	Erlotinib	0.37	uM	LJP5	1	M22	72	hr	1657	4782	5505	0.8686	0.8119
BT-20	Erlotinib	0.37	uM	LJP5	2	M22	72	hr	1657	5205	5505	0.9454	0.9219
BT-20	Erlotinib	0.37	uM	LJP5	3	M22	72	hr	1657	5082	5505	0.9231	0.8899
BT-20	Foretinib	0.37	uM	LJP5	1	H10	72	hr	1657	3440	5505	0.6248	0.4632
BT-20	Foretinib	0.37	uM	LJP5	2	H10	72	hr	1657	2964	5505	0.5384	0.3395
BT-20	Foretinib	0.37	uM	LJP5	3	H10	72	hr	1657	3120	5505	0.5667	0.3800

|<
<<
Previous
Page 33 of 497
Next
>>
>
801 to 825 of 12420 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)